Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: Known and novel aspects of the syndrome

Annals of the New York Academy of Sciences

Volumn 1246, Issue 1, 2011, Pages 77-91

  Kisand, Kai ^a   Peterson, Pärt ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

AIRE; APECED; Chronic mucocutaneous candidiasis; IL 17; IL 22

Indexed keywords

INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22;

ADDISON DISEASE; AIRE GENE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNITY; AUTOSOMAL RECESSIVE DISORDER; DIFFERENTIAL DIAGNOSIS; GASTROINTESTINAL DISEASE; GENE; GENE MUTATION; HUMAN; HYPOPARATHYROIDISM; IMMUNOLOGICAL TOLERANCE; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; PATHOGENESIS; PREVALENCE; REVIEW; THYMOMA;

EID: 84855321087     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06308.x     Document Type: Review

References (136)

1. Notarangelo, L., J.L. Casanova, M.E. Conley, et al. 2006. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J. Allergy Clin. Immunol. 117: 883-896.
2. Thorpe, E.S. & H.E. Handley. 1929. Chronic tetany and chronic mycelial stomatitis in a child aged four and one-half years. Am. J. Dis. Child 38: 328-338.
3. Leonard, M.F. 1946. Chronic idiopathic hypoparathyroidism with superimposed Addison's disease in a child. J. Clin. Endocrinol. Metab. 6: 493-506.
4. Esselborn, V.M., B.H. Landing, J. Whitaker, et al. 1956. The syndrome of familial juvenile hypoadrenocorticism, hypoparathyroidism and superficial moniliasis. J. Clin. Endocrinol. Metab. 16: 1374-1387.
5. Neufeld, M., N. Maclaren & R. Blizzard. 1980. Autoimmune polyglandular syndromes. Pediatr. Ann. 9: 154-162.
6. Ahonen, P., S. Myllarniemi, I. Sipila, et al. 1990. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N. Engl. J. Med. 322: 1829-1836.
7. Perheentupa, J. 2002. APS-I/APECED: the clinical disease and therapy. Endocrinol. Metab. Clin. North Am. 31: 295-320, vi.
8. Zlotogora, J. & M.S. Shapiro. 1992. Polyglandular autoimmune syndrome type I among Iranian Jews. J. Med. Genet. 29: 824-886.
9. Rosatelli, M.C., A. Meloni, A. Meloni, et al. 1998. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum. Genet. 103: 428-434.
10. Perheentupa, J. 2006. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J. Clin. Endocrinol. Metab. 91: 2843-2850.
11. Podkrajsek, K.T., N. Bratanic, C. Krzisnik, et al. 2005. Autoimmune regulator-1 messenger ribonucleic acid analysis in a novel intronic mutation and two additional novel AIRE gene mutations in a cohort of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. J. Clin. Endocrinol. Metab. 90: 4930-4935.
12. Myhre, A.G., M. Halonen, P. Eskelin, et al. 2001. Autoimmune polyendocrine syndrome type 1 (APS I) in Norway. Clin. Endocrinol. 54: 211-217.
13. Stolarski, B., E. Pronicka, L. Korniszewski, et al. 2006. Molecular background of polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome in a Polish population: novel AIRE mutations and an estimate of disease prevalence. Clin. Genet. 70: 348-354.
14. Husebye, E.S., J. Perheentupa, R. Rautemaa, et al. 2009. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J. Intern. Med. 265: 514-529.
15. Peterson, P. & L. Peltonen. 2005. Autoimmune polyendocrinopathy syndrome type 1 (APS1) and AIRE gene: new views on molecular basis of autoimmunity. J. Autoimmun. 25(Suppl): 49-55.
16. Nagamine, K., P. Peterson, H.S. Scott, et al. 1997. Positional cloning of the APECED gene. Nat. Genet. 17: 393-398.
17. Consortium, F.-G.A. 1997. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet. 17: 399-403.
18. Cetani, F., G. Barbesino, S. Borsari, et al. 2001. A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly cosegregating with hypothyroid autoimmune thyroiditis. J. Clin. Endocrinol. Metab. 86: 4747-4752.
19. Boe, A.S., P.M. Knappskog, A.G. Myhre, et al. 2002. Mutational analysis of the autoimmune regulator (AIRE) gene in sporadic autoimmune Addison's disease can reveal patients with unidentified autoimmune polyendocrine syndrome type I. Eur. J. Endocrinol. 146: 519-522.
20. Cervato, S., L. Morlin, M.P. Albergoni, et al. 2010. AIRE gene mutations and autoantibodies to interferon omega in patients with chronic hypoparathyroidism without APECED. Clin. Endocrinol. 73: 630-636.
21. Meager, A., K. Visvalingam, P. Peterson, et al. 2006. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3: e289.
22. Meloni, A., M. Furcas, F. Cetani, et al. 2008. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J. Clin. Endocrinol. Metab. 93: 4389-4397.
23. Toth, B., A.S. Wolff, Z. Halasz, et al. 2010. Novel sequence variation of AIRE and detection of interferon-omega antibodies in early infancy. Clin. Endocrinol. 72: 641-647.
24. Wolff, A.S., M.M. Erichsen, A. Meager, et al. 2007. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J. Clin. Endocrinol. Metab. 92: 595-603.
25. Zhang, L., J.M. Barker, S. Babu, et al. 2007. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin. Immunol. 125: 131-137.
26. Husebye, E.S. & M.S. Anderson. 2011. Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis. Immunity 32: 479-487.
27. Heino, M., P. Peterson, J. Kudoh, et al. 1999. Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla. Biochem. Biophys. Res. Commun. 257: 821-825.
28. Gardner, J.M., J.J. Devoss, R.S. Friedman, et al. 2008. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321: 843-847.
29. Poliani, P.L., K. Kisand, V. Marrella, et al. 2010. Human peripheral lymphoid tissues contain autoimmune regulator-expressing dendritic cells. Am. J. Pathol. 176: 1104-1112.
30. Kyewski, B. & J. Derbinski. 2004. Self-representation in the thymus: an extended view. Nat. Rev. Immunol. 4: 688-698.
31. Bjorses, P., M. Halonen, J.J. Palvimo, et al. 2000. Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am. J. Hum. Genet. 66: 378-392.
32. Bernardi, R. & P.P. Pandolfi. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell. Biol. 8: 1006-1016.
33. Peterson, P., T. Org & A. Rebane. 2008. Transcriptional regulation by AIRE: molecular mechanisms of central tolerance. Nat. Rev. Immunol. 8: 948-957.
34. Podkrajsek, K.T., T. Milenkovic, R.J. Odink, et al. 2008. Detection of a complete autoimmune regulator gene deletion and two additional novel mutations in a cohort of patients with atypical phenotypic variants of autoimmune polyglandular syndrome type 1. Eur. J. Endocrinol. 159: 633-639.
35. Boe Wolff, A.S., B. Oftedal, S. Johansson, et al. 2008. AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes Immun. 9: 130-136.
36. Cihakova, D., K. Trebusak, M. Heino, et al. 2001. Novel AIRE mutations and P450 cytochrome autoantibodies in Central and Eastern European patients with APECED. Hum. Mutat. 18: 225-232.
37. Scott, H.S., M. Heino, P. Peterson, et al. 1998. Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol. Endocrinol. 12: 1112-1119.
38. Peterson, P., J. Pitkanen, N. Sillanpaa, et al. 2004. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity. Clin. Exp. Immunol. 135: 348-357.
39. Ferguson, B.J., C. Alexander, S.W. Rossi, et al. 2008. AIRE's CARD revealed, a new structure for central tolerance provokes transcriptional plasticity. J. Biol. Chem. 283: 1723-1731.
40. Ilmarinen, T., P. Eskelin, M. Halonen, et al. 2005. Functional analysis of SAND mutations in AIRE supports dominant inheritance of the G228W mutation. Hum. Mutat. 26: 322-331.
41. Su, M.A., K. Giang, K. Zumer, et al. 2008. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in AIRE. J. Clin. Invest. 118: 1712-1726.
42. Bottomley, M.J., M.W. Collard, J.I. Huggenvik, et al. 2001. The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation. Nat. Struct. Biol. 8: 626-633.
43. Org, T., F. Chignola, C. Hetenyi, et al. 2008. The autoimmune regulator PHD finger binds to non-methylated histone H3K4 to activate gene expression. EMBO Rep. 9: 370-376.
44. Koh, A.S., A.J. Kuo, S.Y. Park, et al. 2008. AIRE employs a histone-binding module to mediate immunological tolerance, linking chromatin regulation with organ-specific autoimmunity. Proc. Natl. Acad. Sci. USA 105: 15878-15883.
45. Chignola, F., M. Gaetani, A. Rebane, et al. 2009. The solution structure of the first PHD finger of autoimmune regulator in complex with non-modified histone H3 tail reveals the antagonistic role of H3R2 methylation. Nucleic. Acids Res. 37: 2951-2961.
46. Halonen, M., P. Eskelin, A.G. Myhre, et al. 2002. AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J. Clin. Endocrinol. Metab. 87: 2568-2574.
47. Kisand, K., A.S. Boe Wolff, K.T. Podkrajsek, et al. 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207: 299-308.
48. Kisand, K., D. Lilic, J.L. Casanova, et al. 2011. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur. J. Immunol. 41: 1517-1527.
49. Betterle, C., N.A. Greggio & M. Volpato. 1998. Clinical review 93: autoimmune polyglandular syndrome type 1. J. Clin. Endocrinol. Metab. 83: 1049-1055.
50. Wolff, A.S., B.E. Oftedal, K. Kisand, et al. 2010. Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in autoimmune polyendocrine syndrome type I. Scand. J. Immunol. 71: 459-467.
51. Alimohammadi, M., P. Bjorklund, A. Hallgren, et al. 2008. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N. Engl. J. Med. 358: 1018-1028.
52. Gavalas, N.G., E.H. Kemp, K.J. Krohn, et al. 2007. The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 92: 2107-2114.
53. Soderbergh, A., A.G. Myhre, O. Ekwall, et al. 2004. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J. Clin. Endocrinol. Metab. 89: 557-562.
54. Krohn, K., R. Uibo, E. Aavik, et al. 1992. Identification by molecular cloning of an autoantigen associated with Addison's disease as steroid 17 alpha-hydroxylase. Lancet 339: 770-773.
55. Winqvist, O., F.A. Karlsson & O. Kampe. 1992. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 339: 1559-1562.
56. Winqvist, O., J. Gustafsson, F. Rorsman, et al. 1993. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison's disease. J. Clin. Invest. 92: 2377-2385.
57. Proust-Lemoine, E., P. Saugier-Veber, D. Lefranc, et al. 2010. Autoimmune polyendocrine syndrome type 1 in north-western France: AIRE gene mutation specificities and severe forms needing immunosuppressive therapies. Horm. Res. Paediatr. 74: 275-284.
58. Perniola, R., A. Falorni, M.G. Clemente, et al. 2000. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Eur. J. Endocrinol. 143: 497-503.
59. Reimand, K., J. Perheentupa, M. Link, et al. 2008. Testis-expressed protein TSGA10 an auto-antigen in autoimmune polyendocrine syndrome type I. Int. Immunol. 20: 39-44.
60. Bensing, S., S.O. Fetissov, J. Mulder, et al. 2007. Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1. Proc. Natl. Acad. Sci. USA 104: 949-954.
61. Husebye, E.S., G. Gebre-Medhin, T. Tuomi, et al. 1997. Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. J. Clin. Endocrinol. Metab. 82: 147-150.
62. Clemente, M.G., P. Obermayer-Straub, A. Meloni, et al. 1997. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J. Clin. Endocrinol. Metab. 82: 1353-1361.
63. Ekwall, O., H. Hedstrand, L. Grimelius, et al. 1998. Identification of tryptophan hydroxylase as an intestinal autoantigen. Lancet 352: 279-283.
64. Skoldberg, F., G.M. Portela-Gomes, L. Grimelius, et al. 2003. Histidine decarboxylase, a pyridoxal phosphate-dependent enzyme, is an autoantigen of gastric enterochromaffin-like cells. J. Clin. Endocrinol. Metab. 88: 1445-1452.
65. Hedstrand, H., O. Ekwall, J. Haavik, et al. 2000. Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I. Biochem. Biophys. Res. Commun. 267: 456-461.
66. Hedstrand, H., O. Ekwall, M.J. Olsson, et al. 2001. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. J. Biol. Chem. 276: 35390-35395.
67. Alimohammadi, M., N. Dubois, F. Skoldberg, et al. 2009. Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proc. Natl. Acad. Sci. USA 106: 4396-4401.
68. Uibo, R., E. Aavik, P. Peterson, et al. 1994. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J. Clin. Endocrinol. Metab. 78: 323-328.
69. Furmaniak, J., S. Kominami, T. Asawa, et al. 1994. Autoimmune Addison's disease-evidence for a role of steroid 21-hydroxylase autoantibodies in adrenal insufficiency. J. Clin. Endocrinol. Metab. 79: 1517-1521.
70. Gylling, M., T. Tuomi, P. Bjorses, et al. 2000. ss-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J. Clin. Endocrinol. Metab. 85: 4434-4440.
71. Kemp, E.H., N.G. Gavalas, K.J. Krohn, et al. 2009. Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 94: 4749-4756.
72. Husebye, E.S. 2009. Functional autoantibodies cause hypoparathyroidism. J. Clin. Endocrinol. Metab. 94: 4655-4657.
73. Gebre-Medhin, G., E.S. Husebye, J. Gustafsson, et al. 1997. Cytochrome P450IA2 and aromatic l-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I. FEBS Lett. 412: 439-445.
74. Bratland, E., B. Skinningsrud, D.E. Undlien, et al. 2009. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 94: 5117-5124.
75. Bratland, E. & E.S. Husebye. 2011. Cellular immunity and immunopathology in autoimmune Addison's disease. Mol. Cell. Endocrinol. 336: 180-190.
76. Rottembourg, D., C. Deal, M. Lambert, et al. 2010. 21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease. J. Autoimmun. 35: 309-315.
77. Gianani, R. & G.S. Eisenbarth. 2003. Autoimmunity to gastrointestinal endocrine cells in autoimmune polyendocrine syndrome type I. J. Clin. Endocrinol. Metab. 88: 1442-1444.
78. Hogenauer, C., R.L. Meyer, G.J. Netto, et al. 2001. Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. N. Engl. J. Med. 344: 270-274.
79. Collins, S.M., M. Dominguez, T. Ilmarinen, et al. 2006. Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Br. J. Dermatol. 154: 1088-1093.
80. Pavlic, A. & J. Waltimo-Siren. 2009. Clinical and microstructural aberrations of enamel of deciduous and permanent teeth in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Arch. Oral. Biol. 54: 658-665.
81. Perniola, R., G. Tamborrino, S. Marsigliante, et al. 1998. Assessment of enamel hypoplasia in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J. Oral. Pathol. Med. 27: 278-282.
82. Orlova, E.M., A.M. Bukina, E.S. Kuznetsova, et al. 2010. Autoimmune polyglandular syndrome type 1 in Russian patients: clinical variants and autoimmune regulator mutations. Horm. Res. Paediatr. 73: 449-457.
83. Al-Owain, M., N. Kaya, H. Al-Zaidan, et al. 2010. Renal failure associated with APECED and terminal 4q deletion: evidence of autoimmune nephropathy. Clin. Dev. Immunol. 2010: 586342.
84. Ulinski, T., L. Perrin, M. Morris, et al. 2006. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome with renal failure: impact of posttransplant immunosuppression on disease activity. J. Clin. Endocrinol. Metab. 91: 192-195.
85. Di Sabatino, A., R. Carsetti & G.R. Corazza. 2011. Post-splenectomy and hyposplenic states. Lancet 378: 86-97.
86. Rautemaa, R., J. Hietanen, S. Niissalo, et al. 2007. Oral and oesophageal squamous cell carcinoma-a complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral. Oncol. 43: 607-613.
87. Oftedal, B.E., A.S. Wolff, E. Bratland, et al. 2008. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin. Immunol. 129: 163-169.
88. Meager, A., A. Vincent, J. Newsom-Davis, et al. 1997. Spontaneous neutralising antibodies to interferon-alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet 350: 1596-1597.
89. Marx, A., N. Willcox, M.I. Leite, et al. 2010. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 43: 413-427.
90. Kisand, K., M. Link, A.S. Wolff, et al. 2008. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 112: 2657-2666.
91. Zhang, S.Y., S. Boisson-Dupuis, A. Chapgier, et al. 2008. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol. Rev. 226: 29-40.
92. Moschen, A.R., S. Geiger, I. Krehan, et al. 2008. Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology 213: 779-787.
93. Liu, L., S. Okada, X.F. Kong, et al. 2011. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 208: 1635-1648.
94. Puel, A., R. Doffinger, A. Natividad, et al. 2010. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207: 291-297.
95. Ahlgren, K.M., S. Moretti, B.A. Lundgren, et al. 2011. Increased IL-17A secretion in response to Candida albicans in autoimmune polyendocrine syndrome type 1 and its animal model. Eur. J. Immunol. 41: 235-245.
96. Oftedal, B.E., O. Kampe, A. Meager, et al. 2011. Measuring autoantibodies against IL-17F and IL-22 in autoimmune polyendocrine syndrome type I by radioligand binding assay using fusion proteins. Scand. J. Immunol. 74: 327-333.
97. Gaffen, S.L., N. Hernandez-Santos & A.C. Peterson. 2011. IL-17 signaling in host defense against Candida albicans. Immunol. Res. 50: 181-187.
98. Puel, A., S. Cypowyj, J. Bustamante, et al. 2011. Chronic mucocutaneous Candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332: 65-68.
99. Liang, S.C., X.Y. Tan, D.P. Luxenberg, et al. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203: 2271-2279.
100. Conti, H.R., O. Baker, A.F. Freeman, et al. 2011. New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome. Mucosal. Immunol. 4: 448-455.
101. Sonnenberg, G.F., L.A. Fouser & D. Artis. 2011. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12: 383-390.
102. Eyerich, S., J. Wagener, V. Wenzel, et al. 2011. IL-22 and TNF-alpha represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur. J. Immunol. 41: 1894-1901.
103. Eyerich, K., S. Foerster, S. Rombold, et al. 2008. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J. Invest. Dermatol. 128: 2640-2645.
104. Ng, W.F., A. von Delwig, A.J. Carmichael, et al. 2010. Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J. Allergy Clin. Immunol. 126: 1006-1015 e4.
105. Zeng, G., C.Y. Chen, D. Huang, et al. 2011. Membrane-bound IL-22 after de novo production in tuberculosis and anti-Mycobacterium tuberculosis effector function of IL-22+ CD4+ T cells. J. Immunol. 187: 190-199.
106. Nagafuchi, S., K. Umene, F. Yamanaka, et al. 2007. Recurrent herpes simplex virus infection in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy associated with L29P and IVS9-1G>C compound heterozygous autoimmune regulator gene mutations. J. Intern. Med. 261: 605-610.
107. Mazza, C., F. Buzi, F. Ortolani, et al. 2011. Clinical heterogeneity and diagnostic delay of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Clin. Immunol. 139: 6-11.
108. Ward, L., J. Paquette, E. Seidman, et al. 1999. Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J. Clin. Endocrinol. Metab. 84: 844-852.
109. Padeh, S., R. Theodor, A. Jonas, et al. 1997. Severe malabsorption in autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy syndrome successfully treated with immunosuppression. Arch. Dis. Child 76: 532-534.
110. Perniola, R., M. Congedo, A. Rizzo, et al. 2008. Innate and adaptive immunity in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Mycoses 51: 228-235.
111. Hong, M., K.R. Ryan, P.D. Arkwright, et al. 2009. Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. Clin. Exp. Immunol. 156: 40-51.
112. Ramsey, C., S. Hassler, P. Marits, et al. 2006. Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator. Eur. J. Immunol. 36: 305-317.
113. Brannstrom, J., S. Hassler, L. Peltonen, et al. 2006. Defect internalization and tyrosine kinase activation in AIRE deficient antigen presenting cells exposed to Candida albicans antigens. Clin. Immunol. 121: 265-273.
114. Pontynen, N., M. Strengell, N. Sillanpaa, et al. 2008. Critical immunological pathways are downregulated in APECED patient dendritic cells. J. Mol. Med. 86: 1139-1152.
115. Ryan, K.R., M. Hong, P.D. Arkwright, et al. 2008. Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED. Clin. Exp. Immunol. 154: 406-414.
116. Lindh, E., S.M. Lind, E. Lindmark, et al. 2008. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc. Natl. Acad. Sci. USA 105: 18466-18471.
117. Perniola, R., G. Lobreglio, M.C. Rosatelli, et al. 2005. Immunophenotypic characterisation of peripheral blood lymphocytes in autoimmune polyglandular syndrome type 1: clinical study and review of the literature. J. Pediatr. Endocrinol. Metab. 18: 155-164.
118. Tuovinen, H., N. Pontynen, M. Gylling, et al. 2009. Gammadelta T cells develop independently of AIRE. Cell Immunol. 257: 5-12.
119. Sediva, A., D. Cihakova & J. Lebl. 2002. Immunological findings in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and their family members: are heterozygotes subclinically affected? J. Pediatr. Endocrinol. Metab. 15: 1491-1496.
120. Lindh, E., E. Rosmaraki, L. Berg, et al. 2010. AIRE deficiency leads to impaired iNKT cell development. J. Autoimmun. 34: 66-72.
121. Kekalainen, E., H. Tuovinen, J. Joensuu, et al. 2007. A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J. Immunol. 178: 1208-1215.
122. Laakso, S.M., T.T. Laurinolli, L.H. Rossi, et al. 2010. Regulatory T cell defect in APECED patients is associated with loss of naive FOXP3(+) precursors and impaired activated population. J. Autoimmun. 35: 351-357.
123. Ryan, K.R., C.A. Lawson, A.R. Lorenzi, et al. 2005. CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J. Allergy Clin. Immunol. 116: 1158-1159.
124. Mathis, D. & C. Benoist. 2009. AIRE. Annu. Rev. Immunol. 27: 287-312.
125. Laakso, S.M., E. Kekalainen, L.H. Rossi, et al. 2011. IL-7 dysregulation and loss of CD8+ T cell homeostasis in the monogenic human disease autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J. Immunol. 187: 2023-2030.
126. Meager, A., P. Peterson & N. Willcox. 2008. Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. Clin. Exp. Immunol. 154: 141-151.
127. Anderson, M.S. & M.A. Su. 2010. AIRE and T cell development. Curr. Opin. Immunol. 23: 198-206.
128. Liston, A., S. Lesage, J. Wilson, et al. 2003. AIRE regulates negative selection of organ-specific T cells. Nat. Immunol. 4: 350-354.
129. Goodnow, C.C., J. Sprent, B. Fazekas de St Groth, et al. 2005. Cellular and genetic mechanisms of self-tolerance and autoimmunity. Nature 435: 590-597.
130. Teh, C.E., S.R. Daley, A. Enders, et al. 2010. T-cell regulation by casitas B-lineage lymphoma (Cblb) is a critical failsafe against autoimmune disease due to autoimmune regulator (Aire) deficiency. Proc. Natl. Acad. Sci. USA 107: 14709-14714.
131. Rosenthal, F.D., M.K. Davies & A.C. Burden. 1978. Malignant disease presenting as Addison's disease. Br. Med. J. 1: 1591-1592.
132. Spencer, S.J., S. Mesiano, J.Y. Lee, et al. 1999. Proliferation and apoptosis in the human adrenal cortex during the fetal and perinatal periods: implications for growth and remodeling. J. Clin. Endocrinol. Metab. 84: 1110-1115.
133. Strobel, P., A. Murumagi, R. Klein, et al. 2007. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J. Pathol. 211: 563-571.
134. Marx, A., P. Hohenberger, H. Hoffmann, et al. 2010. The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J. Thorac. Oncol. 5: S266-S272.
135. Hill, M.E., H. Shiono, J. Newsom-Davis, et al. 2008. The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics. J. Neuroimmunol. 201-202: 50-56.
136. Shiono, H., Y.L. Wong, I. Matthews, et al. 2003. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int. Immunol. 15: 903-913.